Aura Biosciences
NASDAQ: AURACambridge, US · Founded 2009 · Delaware corporation · 132 employees on LinkedIn · 11 known investors
Find your way into Aura Biosciences
227 people in our graph share verified history with the Aura Biosciences team — schools, employers, funds. One of them is your warm intro.
Josep Maria Echarriunlockedknows Elisabet de los Pinos · together at Universitat de Barcelona (overlapped)
knows the team · via IE Business School
knows the team · via MIT Sloan School of Management
knows the team · via Aura Biosciences
×7knows the team · via Universitat de Barcelona
knows the team · via Icahn School of Medicine at Mount Sinai
Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors. Its lead focus is treating choroidal melanoma, a rare ocular cancer for which no first-line drug therapies currently exist.
Founders & leadership
Aura Biosciences was founded in 2009 by Elisabet de los Pinos, Ph.D. and Elisabet de los Pinos.
ED
Elisabet de los Pinos, Ph.D.Co-founder
ED
Elisabet de los PinosinFounder & CEOElisabet de los Pinos is the founder and former CEO of Aura Biosciences, a clinical-stage biotech developing virus-like drug conjugates to target solid tumors including choroidal melanoma; she previously worked in Eli Lilly's oncology unit on the European launch of the lung cancer drug Alimta and held research fellowships at the Institute of Cancer Research in London, Mount Sinai, and Georgetown. She holds a Ph.D. in molecular biology from the University of Barcelona and an MBA from IE Business School.
MW
Michael WyzgaExecutive
DP
Dale Pfost, Ph.D.Named on SEC filing
AE
Alan E. Walts, Ph.D.Named on SEC filing
LG
Lewis GeffenNamed on SEC filing
PW
Peter WirthNamed on SEC filing
Board
RP
Raj Parekh, Ph.D.Board director
JJ
Joel Jean-Mairet, Ph.D.Board director
AP
Art PappasBoard directorCEO of Pappas Capital and Managing Partner of Pappas Ventures at Chiesi Ventures
AW
Alan WaltsBoard director
SG
Salvador Garcia-AtanceBoard director
Investors · 11
Advent Life SciencesLondon
Chiesi VenturesBoston · $5M
Droia VenturesLeuven · $540K
Foresite CapitalWest Hollywood
Jazzya InvestmentsAlcobendasvia Martin Varsavsky · inferred
MedicxiLondon
Myelin VCMontevideo · $250K – $1Mvia Matias Nisenson · inferred
OrbiMedNew York · $1M – $75M
venBio PartnersSan Francisco
Ysios CapitalBarcelona · $5.4M – $21.6M
Columbus Venture PartnersreportedValenciavia Jose Mesa · inferred
Reported raises · per SEC filings
Form D private placements$190.6M disclosed across 8 of 9 rounds · 2013–2026
▶$80.5MraisedApr 2021 · 41 investors · BiotechnologyRule 506(b)
▶$80.5MraisedApr 2021 · 41 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Karan TakharDirector
- Julie FederExecutive Officer
- Raj Parekh, Ph.D.Director
- Elisabet de los Pinos, Ph.D.Executive Officer, Director
- Giovanni Mariggi, Ph.D.Director
- David JohnsonDirector
- Offering amount
- $80.5M
- Amount sold
- $80.5M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedJul 2020 · 32 investors · BiotechnologyRule 506(b)
▶$10MraisedJul 2020 · 32 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christian SchetterDirector
- Elisabet de los Pinos, Ph.D.Executive Officer, Director
- Raj Parekh, Ph.D.Director
- Giovanni Mariggi, Ph.D.Director
- Julie FederExecutive Officer
- George Golumbeski, Ph.D.Director
- Art PappasDirector
- Joel Jean-Mairet, Ph.D.Director
- Casper BreumDirector
- Offering amount
- $17M
- Amount sold
- $10M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20MraisedApr 2019 · 36 investors · BiotechnologyRule 506(b)
▶$20MraisedApr 2019 · 36 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Raj Parekh, Ph.D.Director
- Casper BreumDirector
- Art PappasDirector
- Julie FederExecutive Officer
- Lewis GeffenExecutive Officer
- Giovanni Mariggi, Ph.D.Director
- Joel Jean-Mairet, Ph.D.Director
- Elisabet de los Pinos, Ph.D.Executive Officer, Director
- Alan E. Walts, Ph.D.Director
- Mark ChinDirector
- Offering amount
- $40M
- Amount sold
- $20M
- First sale
- Apr 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$42.3MraisedDec 2018 · 42 investors · BiotechnologyRule 506(b)
▶$42.3MraisedDec 2018 · 42 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lewis GeffenExecutive Officer
- Casper BreumDirector
- Julie FederExecutive Officer
- Dale Pfost, Ph.D.Director
- Mark ChinDirector
- Art PappasDirector
- Elisabet de los Pinos, Ph.D.Executive Officer, Director
- Joel Jean-Mairet, Ph.D.Director
- Alan E. Walts, Ph.D.Director
- Offering amount
- $42.5M
- Amount sold
- $42.3M
- First sale
- Dec 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11.5MraisedNov 2017 · 38 investors · BiotechnologyRule 506(b)
▶$11.5MraisedNov 2017 · 38 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Raj Parekh, Ph.D.Director
- Michael WyzgaExecutive Officer
- Joel Jean-Mairet, Ph.D.Director
- Jose' Baselga, Ph.D.Director
- Dale Pfost, Ph.D.Director
- Alan E. Walts, Ph.D.Director
- Elisabet de los Pinos, Ph.D.Executive Officer, Director
- Lewis GeffenExecutive Officer
- Peter WirthDirector
- Art PappasDirector
- Offering amount
- $11.5M
- Amount sold
- $11.5M
- First sale
- Sep 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$21MraisedMar 2015 · 21 investors · BiotechnologyRule 506(c)
▶$21MraisedMar 2015 · 21 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Peter B. FinnExecutive Officer
- Alan Walts, Ph.D.Director
- Elisabet de los Pinos, Ph.D.Executive Officer, Director
- Peter WirthDirector
- Javier GarciaDirector
- Joel Jean-Mairet, Ph.D.Director
- Art PappasDirector
- Jose Baselga, Ph.D.Director
- Dale Pfost, Ph.D.Director
- Offering amount
- $34.5M
- Amount sold
- $21M
- Minimum investment
- $25K
- Proceeds to insiders
- $1.2M
- First sale
- Feb 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$4MraisedAug 2014 · 41 investors · BiotechnologyRule 506(c)
▶$4MraisedAug 2014 · 41 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Israel RuizDirector
- Peter B. FinnExecutive Officer
- Jose Baselga, Ph.d.Director
- Peter WirthDirector
- Alan WaltsDirector
- Elisabet de los Pinos, Ph.d.Executive Officer, Director
- Javier GarciaDirector
- Offering amount
- $4M
- Amount sold
- $4M
- Minimum investment
- $25K
- Proceeds to insiders
- $500K
- First sale
- Apr 2014
- Incorporated
- Corporation, Delaware, 2009
- Federal exemptions
- 06c
▶$1.3MraisedJan 2014 · 16 investors · BiotechnologyRule 506(c)
▶$1.3MraisedJan 2014 · 16 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Jose Baselga, Ph.d.Director
- Israel RuizDirector
- Alan WaltsDirector
- Salvador Garcia-AtanceDirector
- Elisabet de los Pinos, Ph.d.Executive Officer, Director
- Peter B. FinnExecutive Officer
- Peter WirthDirector
- Offering amount
- $1.3M
- Amount sold
- $1.3M
- Minimum investment
- $25K
- Proceeds to insiders
- $400.5K
- First sale
- Aug 2013
- Incorporated
- Corporation, Delaware, 2009
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapAro Biotherapeutics28 shared keywordsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
Doximity25 shared keywordsDoximity is the largest verified network of healthcare professionals in the U.S., connecting physicians, PAs, NPs, pharmacists, and medical students across specialties and care settings. The platform provides mobile-first tools for clinical communication, collaboration, and workflow optimization.
Practo22 shared keywordsPracto operates an online healthcare platform offering a directory of verified doctors, appointment booking at hospitals and clinics, online consultations across 20+ specialities, subscription health plans, diagnostic test collection, and medicine delivery. It also provides practice management and hospital information management software for clinics and hospitals.
Companies competing with Aura Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Aura Biosciences, Inc. Q2 2026: Net loss $45.6M, EPS $(0.48) — 10-Q Summarytradingview.com · Aug 2026Frequently asked questions
- What does Aura Biosciences do?
- Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors. Its lead focus is treating choroidal melanoma, a rare ocular cancer for which no first-line drug therapies currently exist.
- Who founded Aura Biosciences?
- Aura Biosciences was founded by Elisabet de los Pinos, Ph.D., Elisabet de los Pinos in 2009.
- Who are Aura Biosciences's investors?
- Aura Biosciences's investors include Advent Life Sciences, Chiesi Ventures, Droia Ventures, Foresite Capital, Jazzya Investments, Medicxi, Myelin VC, OrbiMed and 3 more.
- How much funding has Aura Biosciences raised?
- Aura Biosciences has disclosed $190.6M raised across 8 of its 9 known rounds.
- Where is Aura Biosciences headquartered?
- Aura Biosciences is headquartered in Cambridge, US.